Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05
Valérie Boige(Inserm), Pierre Laurent‐Puig(Inserm), David Malka(Inserm), Michel Barrois(Inserm), Philippe Beaune(Inserm), Marie‐Anne Loriot(Unknown), Jean‐Pierre Pignon(Inserm), Isabelle Miran(Inserm), Delphine Le Corre(Centre de Recherche des Cordeliers), David‐Alexandre Trégouët(Université de Bordeaux), Marine Castaing(Inserm), Michel Ducreux(Université Paris-Saclay), Jean Mendiboure(Inserm), Olivier Bouché(Inserm), Claire Mulot(Inserm)
Cited by 169
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
|New England Journal of Medicine|2003|2.1k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2010|1.9k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k